ARTICLE | Clinical News
NPSP in Phase II/III trial
May 18, 2000 7:00 AM UTC
NPS Pharmaceuticals will begin in June a U.S. Phase II/III trial evaluating various combinations of its ALX1-11 recombinant parathyroid hormone and alendronate, supplied by Merck (MRK), to treat osteo...